CoreMed Corporation

Your Partner for Japan Regulatory,
Development Strategy and Market Access

CoreMed is a Japan based Contract Regulatory and Strategy Development Consulting Firm specifically providing Non-Japanese pharmaceutical, bio-pharmaceutical and medical device companies with state-of-the-art strategic regulatory consulting services.

Announcement

CoreMed Appoints Mr. Kazuhiko Mori as Advisor

CoreMed Corporation is pleased to announce the appointment of Mr. Kazuhiko Mori as Advisor.
Mr. Mori previously served as Councilor for Pharmaceutical Affairs in the Minister’s Secretariat of Japan’s Ministry of Health, Labour and Welfare (MHLW) and as Executive Director of the Japan Pharmaceutical Manufacturers Association (JPMA). Throughout his distinguished career, he has made significant contributions to Japan’s pharmaceutical regulation and industry development.

Drawing on Mr. Mori’s extensive expertise and experience, CoreMed will further strengthen its consulting capabilities in regulatory strategy, regulatory affairs, and the pharmaceutical and healthcare sectors.

We look forward to leveraging his valuable insights to better support our clients and partners.

Comprehensive Support for Pharmaceutical Development

CoreMed offers comprehensive support for all development and regulatory tasks, strategy, PMDA consultation, regulatory submission strategies including CMC, non-clinical, and clinical, and the preparation of regulatory submission documents (CTD M1-M5/eCTD). We handle various regulatory tasks associated with submissions and respond to inquiries through to approval. We also manage changes post-application and approval. All staff members at CoreMed are extraordinarily skilled, talented, creative, and experienced and grapple with projects toward a goal which is regulatory approval under Supreme Quality. Our people at CoreMed are passionately supporting pharmaceutical and biopharmaceutical companies bring products to launch by designing development strategies, nonclinical and clinical strategies for pharmaceuticals and biopharmaceuticals including regenerative medicines.

＞ And More